Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Table 6 Multivariate analyses of prognostic factors for disease-free survival and overall survival in patients with stage III colon cancer who received curative treatment

Variables	Disease-free survival		Variables	Overall survival
Variables	HR (95% CI)	P value	Variables	HR (95% CI)	P value
Age, year (> 60 vs. ≤ 60)	1.787 (0.995–3.209)	0.052	T stage (T4 vs. T1–3)	1.602 (0.465–5.520)	0.455
Gender (male vs. female)	2.322 (1.201–4.492)	0.012	Risk stratification (high vs. low)	3.259 (0.654–6.236)	0.149
Adjuvant chemotherapy (unfinished XELOX vs. modified XELOX)	1.448 (0.787–2.664)	0.235	Adjuvant chemotherapy (unfinished XELOX vs. modified XELOX)	3.869 (1.515–9.880)	0.005
Preoperative serum CA19-9, U/mL (> 24 vs. ≤ 24)	3.089 (1.654–5.770)	< 0.001	Preoperative serum CA19-9, U/mL (> 24 vs. ≤ 24)	2.037 (0.946–4.387)	0.069
Preoperative serum CEA, ng/mL (> 5 vs. ≤ 5)	1.147 (0.617–2.132)	0.666

XELOX oxaliplatin and capecitabine regimen, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, HR hazard ratio, CI confidence interval

ISSN: 2523-3548